You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 17, 2025

Details for Patent: 12,138,239


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,138,239 protect, and when does it expire?

Patent 12,138,239 protects LUMRYZ and is included in one NDA.

This patent has thirty patent family members in ten countries.

Summary for Patent: 12,138,239
Title:Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Abstract:Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Inventor(s):Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François DUBUISSON
Assignee:Flamel Ireland Ltd
Application Number:US18/531,056
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 12,138,239: A Detailed Analysis

Introduction

The United States Patent 12,138,239, titled "MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS," presents a significant innovation in the field of pharmaceuticals. This patent, granted to Flamel Technologies, involves the development of modified release formulations of gamma-hydroxybutyrate (GHB), a compound with various therapeutic applications. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background on Gamma-Hydroxybutyrate (GHB)

GHB is a naturally occurring neurotransmitter and a precursor to the neurotransmitter GABA. It has been used therapeutically for conditions such as narcolepsy and cataplexy. However, its use is often limited by its pharmacokinetic profile, which can result in rapid absorption and peak plasma concentrations, leading to side effects and reduced efficacy.

Scope of the Patent

The patent 12,138,239 focuses on overcoming the pharmacokinetic limitations of GHB by developing modified release formulations. These formulations are designed to provide a more controlled and sustained release of GHB, thereby improving its therapeutic efficacy and reducing side effects.

Key Components of the Invention

  • Modified Release Formulations: The patent describes various formulations that use specific excipients and manufacturing processes to achieve a controlled release of GHB. This includes the use of hydrophilic and hydrophobic polymers, waxes, and other materials to modulate the release rate[4].
  • Pharmacokinetic Improvements: The formulations are engineered to provide a more stable and prolonged plasma concentration of GHB, reducing the peak-to-trough fluctuations that are common with immediate release formulations[4].

Claims of the Patent

The patent includes several claims that define the scope of the invention:

Independent Claims

  • Claim 1 typically describes the composition of the modified release formulation, including the active ingredient GHB and the specific excipients used to achieve the controlled release.
  • Claim 2 might detail the method of manufacturing these formulations, including the steps involved in combining the ingredients and shaping the final product[4].

Dependent Claims

  • These claims further specify the types of excipients, their proportions, and the release profiles that are considered within the scope of the invention. For example, a dependent claim might specify a particular polymer or wax that is used to achieve a specific release rate[4].

Patent Landscape Analysis

To understand the position of this patent within the broader patent landscape, it is essential to conduct a patent landscape analysis.

Step 1: Identify Relevant Patents

This involves searching for patents related to GHB formulations, controlled release technologies, and pharmacokinetic improvements. The analysis would include patents from Flamel Technologies as well as those from competitors and other innovators in the field[3].

Step 2: Categorize and Organize Patents

Patents are categorized based on their technological focus, such as the type of excipients used, the release mechanisms, and the therapeutic applications. This helps in identifying gaps and areas of innovation[3].

Step 3: Analyze Patent Claims and Specifications

A detailed analysis of the claims and specifications of relevant patents is crucial. This step involves comparing the claims of the 12,138,239 patent with those of other patents to determine the unique contributions and potential overlaps[3].

Step 4: Evaluate Patent Strength and Validity

This step involves assessing the strength and validity of the patent claims. Factors such as the novelty, non-obviousness, and enablement of the claims are evaluated. The analysis also considers any prior art that might affect the patent's validity[3].

Step 5: Determine Strategic Implications

The final step is to determine the strategic implications of the patent. This includes understanding how the patent can be used to protect market share, identify potential licensing opportunities, and guide future research and development efforts[3].

Legal Considerations and Patent Eligibility

When evaluating the patentability of inventions like the modified release GHB formulations, it is crucial to consider the legal framework governing patent eligibility.

Section 101 of the Patent Act

Section 101 defines what constitutes patentable subject matter. The Supreme Court has established that laws of nature, natural phenomena, and abstract ideas are not patentable. However, an application of a law of nature or an abstract idea to a known structure or process can be patentable if it includes an "inventive concept" that transforms the process into something more than just the application of the natural law or abstract idea[1][2].

The Alice Test

The Alice test, developed by the Supreme Court, is a two-step process to determine patent eligibility. Step one involves determining whether the claims are directed to an abstract idea. If they are, step two assesses whether the claims include elements that are "significantly more" than the abstract idea itself. In the context of the 12,138,239 patent, the claims would need to demonstrate a specific, inventive application of the controlled release technology that goes beyond mere conventional steps[2].

Key Takeaways

  • Innovative Formulations: The patent 12,138,239 introduces novel modified release formulations of GHB, enhancing its therapeutic efficacy and reducing side effects.
  • Patent Landscape: A thorough patent landscape analysis is essential to understand the competitive environment and strategic implications of this patent.
  • Legal Considerations: The patent must comply with Section 101 of the Patent Act and pass the Alice test to ensure its validity and enforceability.

FAQs

Q: What is the primary innovation of the United States Patent 12,138,239?

A: The primary innovation is the development of modified release formulations of gamma-hydroxybutyrate (GHB) that improve its pharmacokinetic profile.

Q: How does the patent landscape analysis help in understanding this patent?

A: It helps in identifying relevant patents, categorizing and organizing them, analyzing claims and specifications, evaluating patent strength, and determining strategic implications.

Q: What are the key legal considerations for this patent?

A: The patent must comply with Section 101 of the Patent Act and pass the Alice test to ensure it includes an "inventive concept" beyond mere conventional steps.

Q: What is the significance of the Alice test in patent eligibility?

A: The Alice test is a two-step process that determines whether patent claims are directed to an abstract idea and if they include elements that are "significantly more" than the abstract idea itself.

Q: How can this patent be used strategically by Flamel Technologies?

A: It can be used to protect market share, identify licensing opportunities, and guide future research and development efforts in controlled release technologies.

Sources

  1. Mayo v. Prometheus Labs, Full Text with Analysis (BitLaw)
  2. CONTOUR IP HOLDING LLC v. GOPRO, INC., CAFC Opinion
  3. How to perform a patent landscape analysis in 5 key steps, IP Checkups
  4. Untitled - googleapis.com, United States Patent 12,138,239
  5. U.S. Patent Small Claims Court, ACUS Report

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 12,138,239

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
Avadel Cns LUMRYZ sodium oxybate FOR SUSPENSION, EXTENDED RELEASE;ORAL 214755-001 May 1, 2023 RX Yes Yes 12,138,239 ⤷  Try for Free Y ⤷  Try for Free
Avadel Cns LUMRYZ sodium oxybate FOR SUSPENSION, EXTENDED RELEASE;ORAL 214755-002 May 1, 2023 RX Yes No 12,138,239 ⤷  Try for Free Y ⤷  Try for Free
Avadel Cns LUMRYZ sodium oxybate FOR SUSPENSION, EXTENDED RELEASE;ORAL 214755-003 May 1, 2023 RX Yes No 12,138,239 ⤷  Try for Free Y ⤷  Try for Free
Avadel Cns LUMRYZ sodium oxybate FOR SUSPENSION, EXTENDED RELEASE;ORAL 214755-004 May 1, 2023 RX Yes No 12,138,239 ⤷  Try for Free Y ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 1 to 4 of 4 entries

International Family Members for US Patent 12,138,239

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Argentina 109376 ⤷  Try for Free
Australia 2017300845 ⤷  Try for Free
Australia 2020231916 ⤷  Try for Free
Australia 2023203055 ⤷  Try for Free
Brazil 112019000848 ⤷  Try for Free
Brazil 112021013766 ⤷  Try for Free
Canada 3028878 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 7 of 7 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.